BioNTech SE - American Depositary Shares (BNTX)

It has been a volatile year for the biotech.

BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials.

Is bigger always better? Not necessarily.

BioNTech's cancer pipeline is bigger than its COVID-era reputation suggests, and the stock still trades below $100.

Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.

Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term setup as mRNA oncology enters a new phase.

The company is looking to prove it can achieve significant success outside the coronavirus market.

Investors buying this biotech stock now will get its pipeline essentially for free.

BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.

The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter.

Both have attracted considerable attention from Wall Street recently.

The company is coming back into the spotlight thanks to recent developments.

BioNTech is preparing for its next phase.

COVID vaccine demand weakens as BioNTech pivots to oncology with promising clinical data.

BioNTech (NASDAQ:BNTX) reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year quarter also benefited from a one-time compensation payment from Pfizer related to its decision to opt

Could it become as successful in this niche as it was in the coronavirus vaccine market?

Cathie Wood's biotech ETF has largely moved on from the vaccine maker.

They may not remain cheap for too much longer.

It has been a banner year for biotech buyouts, and these are two of the prime targets.

BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2

Investors can find much better opportunities.

This may be an excellent deal for those focused on the long game.